In PIONEER-9, oral semaglutide induced nausea in up to 10% of patients, whereas none of the liraglutide patients had nausea (liraglutide was low-dose however) ( Finally, in a network meta-analysis, several short- and long-acting GLP-1RA were compared regarding efficacy and side effect profile
Fourth, this study did not evaluate comparative effectiveness or cost-effectiveness relative to other treatment strategies, including switching to or initiating other glucose-lowering agents such as GIP/GLP-1 receptor agonists
This semisolid preparation is dispensed in a pump mechanism, ensuring a convenient and controlled application on the skin for localized treatment or absorption of active ingredients
Weight loss with GLP-1 agonists continues accumulating through week 60+
The authors conclude that patient-specific nutrition guidance is essential to prevent unintended health consequences during GLP-1 therapy
Escalates to 2.4 mg over ~1620 weeks